ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TMDX vs NEO // EV/EBITDA & P/E VALUATION

TransMedics Group Inc. (NASDAQ) VS. NeoGenomics Inc. (NASDAQ) • 15-METRIC TALLY: TMDX 8 — NEO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. NEO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TMDX NEO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 59.90% 43.20% +16.70 TMDX /gross-margins <GO>
Return on Invested Capital (ROIC) 18.10% -9.00% +27.10 TMDX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 14.6x — — TIE /valuation <GO>
Free Cash Flow Yield 5.74% -0.94% +6.68 TMDX /fcf-yield <GO>
Operating Margin 17.90% -15.90% +33.80 TMDX /operating-margins <GO>
Net Profit Margin 31.40% -14.80% +46.20 TMDX /net-margins <GO>
Revenue Growth (YoY) 37.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.50 2.72 +0.78 TMDX /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 TMDX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 28.9 51.0 -22.04 NEO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 10.2x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.33B $2.32B $7.4M TMDX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TMDX REV NEO REV TMDX GROSS % NEO GROSS % TMDX FCF NEO FCF
FY 2025 $605.5M $727.3M 59.9% 43.2% $133.6M -$21.8M
FY 2024 $441.5M $660.6M 59.4% 43.9% -$80.9M -$34.0M
FY 2023 $241.6M $0 — — -$13.0M -$2.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
NEO // BETA —